Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708755 | 0.90 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6710407 | 0.89 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6708873 | 0.86 | PDE11A (0.42) | — | |
| SCHEMBL6710476 | 0.85 | PDE11A (0.42) | — | |
| SCHEMBL6708871 | 0.85 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6706968 | 0.84 | FFAR1 (0.41) | AURKARPS6KB1 | |
| SCHEMBL6712268 | 0.84 | PDE11A (0.43) | — | |
| SCHEMBL6708995 | 0.83 | FFAR1 (0.41) | AURKARPS6KB1 | |
| SCHEMBL6708945 | 0.83 | FFAR1 (0.39) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL6710419 | 0.82 | PDE5A (0.43) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777419-B1 | EXHIBIT PHOSPHODIESTERASE V INHIBITION AND CAN BE EMPLOYED FOR THE TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM OR ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | MERCK PATENT GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1357904-A2 | USE OF PYRAZOLO 4,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1343506-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1339410-A1 | USE OF PYRAZOLO 4,3-D]PYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002045716-A1 | USE OF PYRAZOLO[4,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002041880-A2 | USE OF PYRAZOLO[4,3-D]PYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PDE4A 26/4885PDE4B 29/4885PDE4C 53/4885 |
| US-20040023990-A1 | Use of pyrazolo[4,3-d]pyrimidines | P2RX3, HRH2, HRH4 | PDE4A 285/4885PDE4B 498/4885PDE4C 765/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | PDE4A 28/4885PDE4B 43/4885PDE4C 86/4885 |
| US-20040023991-A1 | Use of pyrazolo[4,3-d]pyrimidines | DPYD, TYMP, PNPO | PDE4A 675/4885PDE4B 1005/4885PDE4C 970/4885 |
| US-20040063730-A1 | Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives | PTGIS, PTGIR, PTGER1 | PDE4A 357/4885PDE4B 645/4885PDE4C 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.